Bumetanide: a new loop diuretic (Bumex, Roche Laboratories).
Bumetanide is a recently introduced diuretic that inhibits sodium transport in the thick ascending limb of the loop of Henle. It is structurally and pharmacologically similar to furosemide, but is approximately 40 times as potent on a milligram-for-milligram basis. After oral administration, it is rapidly absorbed, with peak serum concentrations attained at approximately 30 minutes. Its pharmacokinetic parameters are similar to those of furosemide. Bumetanide has demonstrated efficacy in the management of edema associated with congestive heart failure, hepatic cirrhosis, and renal insufficiency. Bumetanide has demonstrated an adverse-reaction profile similar to that of furosemide, although the incidence of hypochloremia and hypokalemia is greater with bumetanide. The incidence of hyperglycemia and ototoxicity is greater with furosemide. The principal indication for bumetanide may be in patients with increased risk of ototoxicity. Cost considerations should relegate bumetanide to a secondary role for the treatment of sodium and fluid retention in most clinical settings.
D000818:Animals; D001702:Biopharmaceutics; D002034:Bumetanide / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D002273:Carcinogens; D055598:Chemical Phenomena; D002621:Chemistry; D003365:Costs and Cost Analysis; D004232:Diuretics / Q000627:therapeutic use*; D004347:Drug Interactions; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy; D007700:Kinetics; D008107:Liver Diseases / Q000188:drug therapy; D009153:Mutagens; D011485:Protein Binding; D013723:Teratogens
D002273:Carcinogens; D004232:Diuretics; D009153:Mutagens; D013723:Teratogens; D002034:Bumetanide